9,090,909 Shares of Common Stock and Warrants to Purchase 6,818,181 Shares of Common Stock Argos Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 29th, 2016 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
Argos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 9,090,909 shares (each, a “Share”) of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”) and (ii) warrants to purchase up to 6,818,181 shares of Common Stock in the form set forth in Exhibit A (each, a “Warrant”). Each Share is being sold together with a Warrant to purchase 0.75 of a share of Common Stock at an exercise price of $5.50 per whole share of Common Stock. The Shares and Warrants are collectively called the “Securities.” The shares of Common Stock underlying the Warrants are called the “Warrant Shares.”
WARRANT AGREEMENTWarrant Agreement • July 29th, 2016 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
WARRANT AGREEMENT, dated as of , 2016 (the “Agreement”), by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), Computershare Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (the “Trust Company” and collectively with Computershare, “Warrant Agent”).
